JANUX THERAPEUTICS
Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response.
JANUX THERAPEUTICS
Industry:
Biotechnology Health Diagnostics Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.januxrx.com
Total Employee:
11+
Status:
Active
Contact:
858-750-4700
Total Funding:
192.44 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Current Employees Featured
David Campbell President, CEO, Director, and Founder @ Janux Therapeutics
President, CEO, Director, and Founder
2017-05-01
Byron Robinson Chief Strategy Officer @ Janux Therapeutics
Chief Strategy Officer
2022-02-01
Founder
Stock Details
Investors List
OrbiMed
OrbiMed investment in Series B - Janux Therapeutics
BVF Partners
BVF Partners investment in Series B - Janux Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Janux Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series B - Janux Therapeutics
Hartford HealthCare Endowment
Hartford HealthCare Endowment investment in Series B - Janux Therapeutics
Bregua Corporation
Bregua Corporation investment in Series B - Janux Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Series B - Janux Therapeutics
Logos Capital
Logos Capital investment in Series B - Janux Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Janux Therapeutics
Avalon Ventures
Avalon Ventures investment in Series B - Janux Therapeutics
Key Employee Changes
Official Site Inspections
http://www.januxrx.com Semrush global rank: 4.53 M Semrush visits lastest month: 2.33 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Janux Therapeutics"
Janux | Tumor-activated T Cell Immunotherapy | About
Janux is a clinical-stage company developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue.See details»
Janux Therapeutics - Crunchbase Company Profile
Janux Therapeutics experienced significant stock price growth, soaring 222% in one day and nearly tripling due to promising trial data for a new prostate cancer drug.See details»
Janux Therapeutics - Overview, News & Similar companies
May 8, 2024 Janux Therapeutics contact info: Phone number: (858) 751-4493 Website: www.januxrx.com What does Janux Therapeutics do? Janux Therapeutics is an innovative …See details»
Janux - Investor Relations - Investors & Media - Go Daddy
Dec 3, 2024 Contact Us. Janux Therapeutics 10955 Vista Sorrento Parkway, Suite 200 San Diego, CA 92130 Send EmailSee details»
Janux Therapeutics, Inc. (JANX) - Yahoo Finance
See the company profile for Janux Therapeutics, Inc. (JANX) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Janux Therapeutics - LinkedIn
Janux is a clinical-stage company developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a …See details»
T Cell Immuno-oncology | Contact - Janux Therapeutics
With its headquarters in San Diego, CA, Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel T cell immunotherapies.See details»
Janux Therapeutics - Craft
Oct 29, 2024 Janux Therapeutics has 1 employees at their 1 location and $8.08 m in annual revenue in FY 2023. See insights on Janux Therapeutics including office locations, …See details»
Janux Therapeutics Announces Updates to Board of Directors
Jul 22, 2024 The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline …See details»
T Cell Immunotherapy | Our Culture - Janux Therapeutics
Get to know the culture at Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel T cell immunotherapies.See details»
Janux - Investor Relations - Investor & Media - Resources
Investors@januxrx.com. Contact Us. Janux Therapeutics 10955 Vista Sorrento Parkway, Suite 200 San Diego, CA 92130 Send Email. Quick Links. SEC Filings. Investor FAQs. Information …See details»
Janux Therapeutics Announces Proposed Public Offering
Dec 3, 2024 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by …See details»
Janux | Tumor-activated T Cell Immunotherapy | Leadership
Janux is developing tumor-activated immunotherapies precision-engineered to direct T cells to kill tumors without impacting a patient's healthy tissue.See details»
Who Owns Janux Therapeutics – CBM
Different owners may have varying levels of involvement in the company's operations and strategic direction, which can impact the speed and agility of decision-making within the …See details»
Janux - Investor Relations - Janux Announces Doses Selected for …
Dec 2, 2024 A replay of the webcast presentation will be available on the Company's website at https://investors.januxrx.com for at least 30 days. Janux’s TRACTr and TRACIr Pipeline …See details»
David Campbell, Ph.D. - Janux Therapeutics
David founded Janux in 2017 to develop tumor-specific cancer therapeutics in order to improve patient safety and efficacy for this important class of drugs.See details»
Janux - Investor Relations - Janux Therapeutics Reports Fourth …
Mar 8, 2024 ameyer@januxrx.com (202) 215-2579 Media: Jessica Yingling, Ph.D. Little Dog Communications Inc. jessica@litldog.com (858) 344-8091 Source: Janux Therapeutics. View …See details»
Janux - Investor Relations - Janux Therapeutics Reports Third …
Nov 6, 2024 Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for …See details»
Scientific Posters and Presentations - Janux Therapeutics
View posters presntations for Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel T cell immunotherapies.See details»